A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia

被引：19
作者：
Mohammad Arbabi
Mohaddeseh Bagheri
Farzin Rezaei
Seyyed-Ali Ahmadi-Abhari
Mina Tabrizi
Farahnaz Khalighi-Sigaroudi
Shahin Akhondzadeh
机构：
[1] Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran 13337, South Kargar Street
[2] Qods Hospital, Kurdistan University of Medical Sciences, Sanandaj
[3] Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran
[4] Institute of Medicinal Plants, Academic Center for Education, Culture and Research (ACECR), Tehran
来源：
Psychopharmacology | 2012年 / 220卷 / 3期
关键词：
Chronic schizophrenia; Modafinil; Negative symptoms;
D O I：
10.1007/s00213-011-2513-z
中图分类号：
学科分类号：
摘要：
Rational In recent years, evidence suggests that modafinil may be useful for certain symptom domains of schizophrenia, especially for the negative and cognitive symptoms. However, the results are not consistent. Objective This study was designed to investigate the effect of modafinil added to risperidone in patients with chronic schizophrenia in a double blind and randomized clinical trial. Methods Participants were inpatients males (35) and females (11), ages 20-49 years at two teaching psychiatric hospital in Iran. All patients were in the active phase of the illness and met DSM-IV-TR criteria for schizophrenia. Patients were allocated in a random fashion 23 patients to risperidone 6 mg/day plus modafinil 200 mg/day and 23 patients to risperidone 6 mg/day plus placebo. The principal measure of outcome was the positive and negative syndrome scale (PANSS). Patients were assessed by a psychiatrist at baseline and after 2, 4, 6 and 8 weeks after the start of medication. Results The modafinil group had significantly greater improvement in the negative symptoms as well as PANSS total scores over the 8-week trial. Therapy with 200 mg/day of modafinil was well tolerated and no clinically important side effects were observed. Conclusion The present study indicates modafinil as a potential adjunctive treatment strategy for treatment of schizophrenia particularly the negative symptoms. Nevertheless, results of larger-controlled trials are needed before recommendation for broad clinical application can be made. This trial is registered with the Iranian Clinical Trials Registry (IRCT138903131556N16). © 2011 Springer-Verlag.
引用
收藏
页码：591 / 598
页数：7
相关论文
共 27 条
  • [1] Abolfazli R., Hosseini M., Ghanizadeh A., Ghaleiha A., Tabrizi M., Raznahan M., Golalizadeh M., Akhondzadeh S., Doubleblind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression, Depress Anxiety, 28, pp. 297-302, (2011)
  • [2] Akhondzadeh S., Pharmacotherapy of schizophrenia: The past, present and future, Curr Drug Therapy, 1, pp. 1-7, (2006)
  • [3] Akhondzadeh S., Rezaei F., Larijani B., Nejatisafa A.A., Kashani L., Abbasi S.H., Correlation between testosterone, gonadotro-pins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia, Schizophr Res, 84, pp. 405-410, (2006)
  • [4] Akhondzadeh S., Tabatabaee M., Amini H., Ahmadi Abhari S.A., Abbasi S.H., Behnam B., Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial, Schizophrenia Research, 90, 1-3, pp. 179-185, (2007)
  • [5] Akhondzadeh S., Ghayyoumi R., Rezaei F., Salehi B., Modabbernia A.H., Maroufi A., Esfandiari G.R., Naderi M., Ghebleh F., Tabrizi M., Rezazadeh S.A., Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: A double-blind randomized placebo-controlled trial, Psychophar-macology, 213, pp. 809-815, (2011)
  • [6] Diagnostic and Statistical Manual of Mental Disorders, (2000)
  • [7] Amiri S., Mohammadi M.R., Mohammadi M., Nouroozinejad G.H., Kahbazi M., Akhondzadeh S., Modafinil as a treatment for attention-deficit/hyperactivity disorder in children and adolescents: A double blind, randomized clinical trial, Prog Neuro-psychopharmacol Biol Psychiatry, 32, pp. 145-149, (2008)
  • [8] Ballon J.S., Feifel D., A systematic review of modafinil: Potential clinical uses and mechanisms of action, J Clin Psychiatry, 67, pp. 554-666, (2006)
  • [9] Buckley P.F., Stahl S.M., Pharmacological treatment of negative symptoms of schizophrenia: Therapeutic opportunity or Cul-de-sac?, Acta Psychiatrica Scandinavica, 115, 2, pp. 93-100, (2007)
  • [10] Chouinard G., Ross-Chouinard A., Annables L., Jones B.D., Extrapyramidal symptoms rating scale (abstract), Can J Neurol Sci, 7, (1980)
123